Search Results for: Ruxolitinib

GB2064 Displays Preliminary Efficacy, Tolerability in Myelofibrosis

Posted on by

January 16, 2024 Kyle Doherty The potential first-in-class, oral, lysyl oxidase-like 2 (LOXL2) inhibitor GB2064 displayed efficacy with a generally acceptable tolerability profile in the treatment of patients with myelofibrosis, according to topline findings from the phase 2a MYLOX-1 trial (NCT04679870).1 Among evaluable patients with myelofibrosis who were treated with GB2064 monotherapy for a minimum […]

Karyopharm

 

Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer. Our primary focus is on developing novel drugs that we hope will help treat patients with certain blood cancers or solid tumor malignancies.

Karyopharm Therapeutics is investigating the safety and efficacy of selinexor, a selective inhibitor of nuclear export, in combination with ruxolitinib in treatment-naïve patients with myelofibrosis.

INCA-033989 by Incyte for Myelofibrosis: Likelihood of Approval

Posted on by

January 12, 2024 INCA-033989 is under clinical development by Incyte and currently in Phase I for Myelofibrosis. According to GlobalData, Phase I drugs for Myelofibrosis have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how INCA-033989’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication […]

Transfusion Independence With Momelotinib Impacts OS in Myelofibrosis

Posted on by

January 11, 2024 Targeted Oncology Staff DISCUSSION QUESTION How do the most recent data on Janus kinase (JAK) inhibitors support/change your approach to treating patients?​ DRAUPADI TALREJA, MD: I’m all for momelotinib [Ojjaara]. I was never for ruxolitinib [Jakafi] but there was nothing else available, so I used it. HARIS ALI, MD: Would you use momelotinib in the […]

What is Cytoreduction in MPNs?

Posted on by

December 25, 2023 Alex Biese Dr. Douglas Tremblay of the Ichan School of Medicine explains the necessity of cytoreductive therapy for patients with MPNs such as essential thrombocythemia and polycythemia vera. Cytoreduction is crucial for preventing serious complications for patients with essential thrombocythemia (ET) and polycythemia vera (PV) — both types of blood cancers that […]

Polycythemia Vera: Barriers to and Strategies for Optimal Management

Posted on by

Andrea Duminuco,1,2 Patrick Harrington,1 Claire Harrison,1 Natalia Curto-Garcia1 1Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 2Haematology with BMT Unit, A.O.U. Policlinico “G.Rodolico-San Marco”, Catania, Italy Correspondence: Claire Harrison, Guys’ and St Thomas’ Hospital, London, SE1 9RT, UK, Tel +207 188 2742, Email Claire.harrison@gstt.nhs.uk Abstract: Polycythemia vera (PV) is a subtype of myeloproliferative neoplasms characterized by impaired […]

Preliminary data shows lowered cytokine levels in myelofibrosis with PIM1 kinase inhibitor

Posted on by

December 19, 2023 SAN DIEGO — Treatment with a selective PIM1 kinase inhibitor showed positive clinical reactions in a sample of 23 patients with relapsed/refractory myelofibrosis, according to preliminary data presented at ASH Annual Meeting. TP-3654, an oral investigational highly selective PIM1 kinase inhibitor, is the subject of the phase 1/phase 2 study evaluating monotherapy […]

New therapies against myelofibrosis, a blood cancer that risks evolving into acute leukemia – breaking latest news

Posted on by

December 13, 2023 Myelofibrosis is a chronic myeloproliferative neoplasm which every year is diagnosed in approximately one thousand Italians, mostly in their sixties, but many cases occur in young people. There are therapies capable of keeping the disease under control even for years, but two important problems remain open: preventing the disease from evolving into […]

MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

Posted on by

Pelabresib and ruxolitinib combination significantly reduced spleen size, with an SVR35 response rate nearly double that of placebo plus ruxolitinib Showed a strong positive trend in reducing symptom burden and a twofold increase in patients achieving both SVR35 and TSS50 versus placebo plus ruxolitinib Improved measures of anemia, including higher hemoglobin response rates, fewer patients […]

Navitoclax Combo Significantly Reduces Spleen Volume in Myelofibrosis

Posted on by

December 10, 2023 Silas Inman Combining navitoclax with ruxolitinib produced significant reductions in spleen volume by at least 35% at week 24 (SVR35W24) compared with ruxolitinib plus placebo but did not lead to significant changes in total symptom score (TSS) in those with myelofibrosis, according to data from the phase 3 TRANSFORM-1 study (NCT04472598) presented […]